Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017
Summary In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2019-07, Vol.44 (5), p.e189-e192 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e192 |
|---|---|
| container_issue | 5 |
| container_start_page | e189 |
| container_title | Clinical and experimental dermatology |
| container_volume | 44 |
| creator | Ma, J. E. Ernste, F. C. Davis, M. D. P. Wetter, D. A. |
| description | Summary
In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well‐tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC. |
| doi_str_mv | 10.1111/ced.13782 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2112190025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2112190025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-7a8d68201f95d91a5f27bb6e6786e3cde7154296bbaf2c9456e5229c687594483</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy1URJfCgRdAlnoBibT-E9sxN7SUFqkVl3K2HGeiukribSam7I0n4MIb8iS4bHupVB88kufzp9H8CHnD2REv5zhAd8SlacQzsuJSq0oIyfbIiklmKm1ls09eIl4zxiU36gXZl0woLnS9Ir8v0yYGP1BMXcwjXa5iwjz0fgHap5mWVohTwog05KXcHjGFWNodvY3LFfV5SXEc8wQ0pGmCsMQfQAuJGWgXETwCfixeoBd-m-h6iFMMFH5uYI4wBfhABePi768_pZhX5HnvB4TX9_WAfP9ycrk-q86_nX5dfzqvglRSVMY3nW7Kh96qznKvemHaVoM2jQYZOjBc1cLqtvW9CLZWGpQQNujGKFvXjTwg73bezZxuMuDixogBhsFPkDI6wbnglpU1FfTwEXqd8jyV6VxZs-WMWXlHvd9RYU6IM_RuM8fRz1vHmbsLyZWQ3P-QCvv23pjbsbw-kA-pFOB4B9zGAbZPm9z65PNO-Q-uvpvT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2239100935</pqid></control><display><type>article</type><title>Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Ma, J. E. ; Ernste, F. C. ; Davis, M. D. P. ; Wetter, D. A.</creator><creatorcontrib>Ma, J. E. ; Ernste, F. C. ; Davis, M. D. P. ; Wetter, D. A.</creatorcontrib><description>Summary
In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well‐tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/ced.13782</identifier><identifier>PMID: 30251264</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Administration, Cutaneous ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Allergies ; Arthritis, Juvenile - complications ; Arthritis, Rheumatoid - complications ; Autoimmune Diseases - complications ; Calcinosis ; Calcinosis - complications ; Calcinosis - drug therapy ; Case reports ; Chelating Agents - therapeutic use ; Connective tissue diseases ; Connective Tissue Diseases - complications ; Connective tissues ; Dermatomyositis - complications ; Female ; Humans ; Irritation ; Lupus Erythematosus, Systemic - complications ; Male ; Middle Aged ; Pain ; Patients ; Retrospective Studies ; Scleroderma, Systemic - complications ; Skin ; Skin Diseases, Metabolic - complications ; Skin Diseases, Metabolic - drug therapy ; Sodium ; Sodium thiosulfate ; Thiosulfate ; Thiosulfates - therapeutic use ; Undifferentiated Connective Tissue Diseases - complications ; Young Adult</subject><ispartof>Clinical and experimental dermatology, 2019-07, Vol.44 (5), p.e189-e192</ispartof><rights>2018 British Association of Dermatologists</rights><rights>2018 British Association of Dermatologists.</rights><rights>Copyright © 2019 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-7a8d68201f95d91a5f27bb6e6786e3cde7154296bbaf2c9456e5229c687594483</citedby><cites>FETCH-LOGICAL-c3532-7a8d68201f95d91a5f27bb6e6786e3cde7154296bbaf2c9456e5229c687594483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30251264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, J. E.</creatorcontrib><creatorcontrib>Ernste, F. C.</creatorcontrib><creatorcontrib>Davis, M. D. P.</creatorcontrib><creatorcontrib>Wetter, D. A.</creatorcontrib><title>Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary
In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well‐tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.</description><subject>Administration, Cutaneous</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Allergies</subject><subject>Arthritis, Juvenile - complications</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Autoimmune Diseases - complications</subject><subject>Calcinosis</subject><subject>Calcinosis - complications</subject><subject>Calcinosis - drug therapy</subject><subject>Case reports</subject><subject>Chelating Agents - therapeutic use</subject><subject>Connective tissue diseases</subject><subject>Connective Tissue Diseases - complications</subject><subject>Connective tissues</subject><subject>Dermatomyositis - complications</subject><subject>Female</subject><subject>Humans</subject><subject>Irritation</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pain</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Scleroderma, Systemic - complications</subject><subject>Skin</subject><subject>Skin Diseases, Metabolic - complications</subject><subject>Skin Diseases, Metabolic - drug therapy</subject><subject>Sodium</subject><subject>Sodium thiosulfate</subject><subject>Thiosulfate</subject><subject>Thiosulfates - therapeutic use</subject><subject>Undifferentiated Connective Tissue Diseases - complications</subject><subject>Young Adult</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQhy1URJfCgRdAlnoBibT-E9sxN7SUFqkVl3K2HGeiukribSam7I0n4MIb8iS4bHupVB88kufzp9H8CHnD2REv5zhAd8SlacQzsuJSq0oIyfbIiklmKm1ls09eIl4zxiU36gXZl0woLnS9Ir8v0yYGP1BMXcwjXa5iwjz0fgHap5mWVohTwog05KXcHjGFWNodvY3LFfV5SXEc8wQ0pGmCsMQfQAuJGWgXETwCfixeoBd-m-h6iFMMFH5uYI4wBfhABePi768_pZhX5HnvB4TX9_WAfP9ycrk-q86_nX5dfzqvglRSVMY3nW7Kh96qznKvemHaVoM2jQYZOjBc1cLqtvW9CLZWGpQQNujGKFvXjTwg73bezZxuMuDixogBhsFPkDI6wbnglpU1FfTwEXqd8jyV6VxZs-WMWXlHvd9RYU6IM_RuM8fRz1vHmbsLyZWQ3P-QCvv23pjbsbw-kA-pFOB4B9zGAbZPm9z65PNO-Q-uvpvT</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Ma, J. E.</creator><creator>Ernste, F. C.</creator><creator>Davis, M. D. P.</creator><creator>Wetter, D. A.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201907</creationdate><title>Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017</title><author>Ma, J. E. ; Ernste, F. C. ; Davis, M. D. P. ; Wetter, D. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-7a8d68201f95d91a5f27bb6e6786e3cde7154296bbaf2c9456e5229c687594483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Administration, Cutaneous</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Allergies</topic><topic>Arthritis, Juvenile - complications</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Autoimmune Diseases - complications</topic><topic>Calcinosis</topic><topic>Calcinosis - complications</topic><topic>Calcinosis - drug therapy</topic><topic>Case reports</topic><topic>Chelating Agents - therapeutic use</topic><topic>Connective tissue diseases</topic><topic>Connective Tissue Diseases - complications</topic><topic>Connective tissues</topic><topic>Dermatomyositis - complications</topic><topic>Female</topic><topic>Humans</topic><topic>Irritation</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pain</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Scleroderma, Systemic - complications</topic><topic>Skin</topic><topic>Skin Diseases, Metabolic - complications</topic><topic>Skin Diseases, Metabolic - drug therapy</topic><topic>Sodium</topic><topic>Sodium thiosulfate</topic><topic>Thiosulfate</topic><topic>Thiosulfates - therapeutic use</topic><topic>Undifferentiated Connective Tissue Diseases - complications</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, J. E.</creatorcontrib><creatorcontrib>Ernste, F. C.</creatorcontrib><creatorcontrib>Davis, M. D. P.</creatorcontrib><creatorcontrib>Wetter, D. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, J. E.</au><au>Ernste, F. C.</au><au>Davis, M. D. P.</au><au>Wetter, D. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2019-07</date><risdate>2019</risdate><volume>44</volume><issue>5</issue><spage>e189</spage><epage>e192</epage><pages>e189-e192</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><abstract>Summary
In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well‐tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30251264</pmid><doi>10.1111/ced.13782</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2019-07, Vol.44 (5), p.e189-e192 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2112190025 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Administration, Cutaneous Adolescent Adult Aged Aged, 80 and over Allergies Arthritis, Juvenile - complications Arthritis, Rheumatoid - complications Autoimmune Diseases - complications Calcinosis Calcinosis - complications Calcinosis - drug therapy Case reports Chelating Agents - therapeutic use Connective tissue diseases Connective Tissue Diseases - complications Connective tissues Dermatomyositis - complications Female Humans Irritation Lupus Erythematosus, Systemic - complications Male Middle Aged Pain Patients Retrospective Studies Scleroderma, Systemic - complications Skin Skin Diseases, Metabolic - complications Skin Diseases, Metabolic - drug therapy Sodium Sodium thiosulfate Thiosulfate Thiosulfates - therapeutic use Undifferentiated Connective Tissue Diseases - complications Young Adult |
| title | Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A26%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topical%20sodium%20thiosulfate%20for%20calcinosis%20cutis%20associated%20with%20autoimmune%20connective%20tissue%20diseases:%20the%20Mayo%20Clinic%20experience,%202012%E2%80%932017&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Ma,%20J.%20E.&rft.date=2019-07&rft.volume=44&rft.issue=5&rft.spage=e189&rft.epage=e192&rft.pages=e189-e192&rft.issn=0307-6938&rft.eissn=1365-2230&rft_id=info:doi/10.1111/ced.13782&rft_dat=%3Cproquest_cross%3E2112190025%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2239100935&rft_id=info:pmid/30251264&rfr_iscdi=true |